News | May 22, 2026
OncoSil secures TGA approval for pancreatic cancer device
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
New CE-marked algorithm for the Azurion platform delivers improved image quality with over 50% lower radiation dose compared to the lowest settings on ClarityIQ
The development comes as stroke remains one of the world’s biggest health threats
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
Subscribe To Our Newsletter & Stay Updated
